Another setback for Spectrum's remaining pipeline after Rolontis BLA withdrawal

Spectrum said Friday that it withdrew a BLA for Rolontis eflapegrastim to treat chemotherapy-induced neutropenia.

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI)

Read the full 185 word article

User Sign In